Epac and cAMP signalosomes in different subcellular compartments contribute to cardiac and lung diseases, including cardiomyocyte hypertrophy and arrhythmia.
In vitro Epac findings in cardiac and lung cells warrant targeted in vivo studies; leaves open clinical translation.
Evidence collected over the last ten years indicates that Epac and cAMP scaffold proteins play a critical role in integrating and transducing multiple signaling pathways at the basis of cardiac and lung physiopathology. Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy and arrhythmia, initially described in vitro, have been confirmed in genetically modified mice for Epac1 and Epac2. Similar recent findings have been collected in the lung. The following sections will describe how Epac and cAMP signalosomes in different subcellular compartments may contribute to cardiac and lung diseases.
No takes yet. Share an insight, caveat, or question.
Laudette et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: